Miragen Therapeutics (MGEN) Rating Lowered to Hold at ValuEngine
Miragen Therapeutics (NASDAQ:MGEN) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
Other research analysts also recently issued reports about the company. Wedbush reiterated a “buy” rating and set a $19.00 target price on shares of Miragen Therapeutics in a research note on Wednesday, August 8th. Cann reiterated a “buy” rating and set a $19.00 target price on shares of Miragen Therapeutics in a research note on Monday, August 6th. Finally, Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research note on Wednesday, July 18th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $15.34.
Shares of NASDAQ MGEN opened at $5.23 on Wednesday. The company has a quick ratio of 18.98, a current ratio of 18.98 and a debt-to-equity ratio of 0.15. Miragen Therapeutics has a 12 month low of $4.38 and a 12 month high of $10.70. The company has a market cap of $170.73 million, a PE ratio of -3.79 and a beta of 1.33.
In other news, Director Thomas E. Hughes purchased 10,000 shares of Miragen Therapeutics stock in a transaction that occurred on Thursday, October 11th. The stock was acquired at an average cost of $4.77 per share, for a total transaction of $47,700.00. Following the purchase, the director now directly owns 12,827 shares of the company’s stock, valued at approximately $61,184.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 18.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MGEN. Engineers Gate Manager LP bought a new stake in Miragen Therapeutics in the 2nd quarter valued at $106,000. Citadel Advisors LLC bought a new stake in Miragen Therapeutics in the 1st quarter valued at $117,000. Raymond James & Associates bought a new stake in Miragen Therapeutics in the 2nd quarter valued at $135,000. BSW Wealth Partners bought a new stake in Miragen Therapeutics in the 2nd quarter valued at $143,000. Finally, Rhumbline Advisers boosted its stake in Miragen Therapeutics by 77.9% in the 2nd quarter. Rhumbline Advisers now owns 22,845 shares of the medical research company’s stock valued at $146,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 37.03% of the company’s stock.
Miragen Therapeutics Company Profile
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.